HS-10370 + adebrelimab + pemetrexed + cisplatin

This is a **combination regimen** comprising four agents: - **HS-10370**, a selective, covalent, orally bioavailable small molecule inhibitor of KRAS G12C, showing antitumor activity in KRAS G12C-mutant advanced solid tumors, especially non-small cell lung cancer. Developed as an investigational targeted therapy, it acts as a precision inhibitor against a common driver mutation in lung cancer[1][4][8]. - **Adebrelimab**, a fully human anti-PD-L1 monoclonal antibody (not directly described in the retrieved results but known by convention), developed for immunotherapy in various cancers. - **Pemetrexed**, a multitargeted antifolate chemotherapy agent disrupting folate-dependent metabolic processes essential for cell replication. Used in combination with cisplatin for treatment of non-small cell lung cancer and malignant pleural mesothelioma[2][3][5][9]. - **Cisplatin**, a platinum-based chemotherapy agent causing DNA crosslinking and apoptosis in rapidly dividing cells[2][3][5][9]. This multidrug regimen combines **targeted therapy (KRAS inhibition)**, **immune checkpoint blockade** (PD-L1 inhibition), and **cytotoxic chemotherapy**, aiming for synergistic antitumor effects in advanced solid tumors—particularly NSCLC with KRAS G12C mutations.